Epizyme Inc.'s ability to collect its outstanding accounts receivable from its corporate clients, has improved in the second quarter 2022 to a ratio of 7.85, above the company average. This is a clear sign of healthy business climate in the Major Pharmaceutical Preparations industry and improving liquidity at their respective customers, during the second quarter 2022. Average receivable collection period, for the Epizyme in Jun 30 2022 quarter, has decreased to 46 days, compared to 54 days, in the Mar 31 2022 quarter.

If we take a look into Healthcare sector 202 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio remained unchanged relative to the previous period at no. 1725.

What is Receivable Turnover Ratio?
What is Epizyme Inc. Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

EPZM Receivables Turnover Ratio	(Jun 30 2022) II. Quarter	(Mar 31 2022) I. Quarter	(Dec 31 2021) IV. Quarter	(Sep 30 2021) III. Quarter	(Jun 30 2021) II. Quarter
Y / Y Receivable Change	57.47 %	-39.55 %	111.66 %	-27.74 %	307.5 %
Y / Y Revenue Change	111.59 %	13.96 %	38.33 %	45.85 %	427.36 %
Receivable Turnover Ratio (TTM)	7.85	6.72	5.59	5.87	5.3
EPZM's Total Ranking	# 1725	# 1725	# 2643	# 1721	# 2037
Accounts Receivable average collection period days	47	54	65	62	69
Seq. Receivable Change	89.94 %	-10.19 %	97.24 %	-53.2 %	-27.09 %
Seq. Revenue Change	216.56 %	-24.94 %	122.75 %	-60.02 %	70.49 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 89
Healthcare Sector	# 203
Overall Market	# 1725

Receivable Turnover Ratio Statistics
High	Average	Low
17.17	6.84	2
(March 31, 2015)		(Sep 30 2019)

EPZM Company Profile • Back to EPZM Efficiency Comparisons • Compare EPZM Receivables Turnover Ratio to its Competitors

Financial Statements
Epizyme's Accounts Receivable	$ 11 Millions	Visit EPZM's Balance sheet
Epizyme's Sales TTM	$ 53 Millions	Visit EPZM's Income Statement
Sources of EPZM's Revenues		Visit EPZM's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
EPZM's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
EPZM's Growth Rates	EPZM's Roa	EPZM's Inventory Turnover Ratio	EPZM's Dividend Comparisons
EPZM's Profitability Ratios	EPZM's Roi	EPZM's Asset Turnover Ratio	EPZM's Dividend Growth
EPZM's Valuation Ratios	EPZM's Roe	EPZM's Financial Strength Ratios	EPZM's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Jun 30 2022, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Jun 30 2022	Receivable at quarter ending Jun 30 2022
Nurix Therapeutics Inc	12.90	$ 38.701 Millions	$ 3.000 Millions
Clene Inc	12.79	$ 0.374 Millions	$ 0.029 Millions
Cano Health Inc	12.43	$ 2,329.781 Millions	$ 187.448 Millions
Spyre Therapeutics Inc	12.19	$ 7.030 Millions	$ 0.577 Millions
Avita Medical Inc	12.18	$ 33.198 Millions	$ 2.725 Millions
Merus N v	11.84	$ 52.717 Millions	$ 4.453 Millions
Abiomed Inc	11.73	$ 1,056.317 Millions	$ 90.058 Millions
Semler Scientific inc	11.72	$ 54.377 Millions	$ 4.638 Millions
Clearside Biomedical Inc	11.65	$ 29.492 Millions	$ 2.531 Millions
Cadre Holdings inc	11.55	$ 424.829 Millions	$ 36.774 Millions
Inogen Inc	11.54	$ 353.269 Millions	$ 30.621 Millions
Lifeloc Technologies Inc	11.46	$ 7.856 Millions	$ 0.685 Millions
Viveve Medical Inc	11.39	$ 6.758 Millions	$ 0.593 Millions
Karyopharm Therapeutics Inc	11.20	$ 251.307 Millions	$ 22.430 Millions
Ultragenyx Pharmaceutical Inc	11.20	$ 334.314 Millions	$ 29.848 Millions
Longeveron Inc	11.15	$ 1.277 Millions	$ 0.115 Millions
National Healthcare Corp	11.14	$ 1,110.513 Millions	$ 99.665 Millions
Icu Medical Inc	11.11	$ 1,780.711 Millions	$ 160.240 Millions
Emmaus Life Sciences Inc	11.10	$ 16.307 Millions	$ 1.469 Millions
Caremax Inc	11.10	$ 560.042 Millions	$ 50.459 Millions
Integrated Biopharma Inc	11.07	$ 56.246 Millions	$ 5.082 Millions
Protalix Biotherapeutics inc	10.73	$ 45.441 Millions	$ 4.233 Millions
Precipio inc	10.70	$ 9.487 Millions	$ 0.887 Millions
Nascent Biotech Inc	10.67	$ 2.000 Millions	$ 0.188 Millions
Cyclerion Therapeutics Inc	10.66	$ 1.897 Millions	$ 0.178 Millions
U s Stem Cell Inc	10.56	$ 0.129 Millions	$ 0.012 Millions
Cartesian Therapeutics Inc	10.55	$ 127.636 Millions	$ 12.096 Millions
Chemocentryx Inc.	10.55	$ 74.560 Millions	$ 7.067 Millions
Escalon Medical Corp	10.55	$ 10.703 Millions	$ 1.015 Millions
Procyon Corporation	10.50	$ 4.842 Millions	$ 0.461 Millions

Date modified: 2026-08-29T17:17:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.